API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

14 clusters · 54 sources · 52 days · First seen · Last updated

Evonik corporate investment and BASF takeover interest

Overview

German chemical company Evonik has undertaken significant operational and strategic developments. In mid-September 2026, the company announced an 80 million euro investment in its Slovenská Ľupča plant in Slovakia to expand biotechnological capacities, expected to be completed in early 2028. Following reports of a potential takeover, Evonik confirmed on September 25, 2026, that BASF has made a non-binding approach to acquire the company through a voluntary public takeover bid. While initial reports suggested no concrete discussions were taking place, by September 28, both companies confirmed that exploratory talks are underway. On September 28, Evonik rejected an initial non-binding offer of approximately €22.15 per share, which would value the company at roughly €14.2 billion including debt. Management stated the bid did not “fully reflect the strategic value of their high-margin specialty chemical business.” The potential acquisition has triggered significant political backlash in North Rhine-Westphalia. Jochen Ott, chairman of the SPD parliamentary group, criticized the move as an “attack on the lifeblood of the Ruhr area” and warned against the “sell-off” of the region’s industrial base. By October 7, 2026, the SPD proposed that the state government consider becoming a shareholder in Evonik, potentially partnering with the RAG-Stiftung to establish a controlling interest of more than 50 percent. By late October 2026, reports indicated BASF increased its bid to €24 per share, valuing the potential deal at approximately €11 billion. In early November 2026, Evonik officially rejected the takeover attempt. Interim CEO Claus Rettig reaffirmed the decision, stating that industry trends favor focus over sheer size and that internal projections suggest the company can deliver value exceeding the current offer. Evonik leadership also criticized the timing of the offer, which followed the announcement that CEO Christian Kullmann would be temporarily unavailable due to illness, describing the timing as “really strange.”

Entities

Evonik · BASF · RAG-Stiftung · Markus Kamieth · Claus Rettig

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. [BUSINESS] 3 sources
    Evonik rejects takeover offer from BASF

    Evonik interim CEO Claus Rettig has rejected a 24 euro per share takeover offer from BASF, maintaining that the company will pursue independence and focus on strategic growth.

  2. [BUSINESS] 9 sources
    Evonik rejects BASF takeover bid and criticizes timing

    Evonik has rejected a takeover bid from BASF, criticizing the timing of the offer following the medical leave of its CEO. Evonik remains committed to its independence despite the approach.

  3. [BUSINESS] 7 sources
    Evonik rejects takeover bid from BASF

    Evonik has rejected a takeover attempt by BASF, opting to remain an independent company despite a reported offer of 24 euros per share.

  4. [BUSINESS] 22 sources
    BASF raises profit forecast following strong third quarter

    BASF raised its 2026 EBITDA forecast to EUR 7.4-7.8 billion after a strong third quarter driven by higher prices and shifting demand due to the Iran conflict. The company is also pursuing an Evonik acquisition.

  5. [BUSINESS] 2 sources
    Evonik considers potential BASF takeover and Ashland acquisition

    Evonik is reportedly weighing a potential takeover offer from BASF and a possible multi-billion dollar acquisition of Ashland in the US, while also launching new dental PEEK materials.

  6. [BUSINESS] 2 sources
    BASF reportedly increases takeover bid for Evonik to 24 euros per share

    BASF has reportedly raised its takeover bid for Evonik to 24 euros per share, a move that could result in the largest merger in the German chemical sector.

  7. [BUSINESS] 2 sources
    BASF considers higher takeover bid for Evonik pending audit

    BASF is reportedly willing to raise its takeover bid for Evonik, contingent on a formal audit of the specialty chemicals firm's books.

  8. [BUSINESS] 4 sources
    BASF offers job guarantees to advance Evonik takeover bid

    BASF is offering to honor Evonik’s job and site guarantees to facilitate a takeover, though major shareholder RAG-Stiftung remains neutral as Evonik seeks a higher offer.

  9. [BUSINESS] 5 sources
    BASF takeover bid for Evonik rejected by major shareholder

    BASF’s 10.3 billion euro takeover bid for Evonik has been rejected by Evonik management and the RAG-Stiftung, drawing political concern in North Rhine-Westphalia over industrial independence.

  10. [BUSINESS] 6 sources
    BASF and Evonik face potential merger amid calls for state intervention

    BASF is exploring a potential takeover of Evonik to bolster competitiveness, prompting the SPD to propose state ownership in Evonik to protect regional jobs and industrial stability.

  11. [BUSINESS] 4 sources
    BASF takeover bid for Evonik sparks political backlash in Germany

    BASF's potential takeover of Evonik has sparked political backlash in Germany, with officials warning it threatens the industrial stability of the Ruhr region.

  12. [BUSINESS] 20 sources
    Evonik rejects BASF takeover bid of 10.3 billion euros

    BASF's non-binding takeover bid for Evonik, valued at approximately 10.3 billion euros, has been rejected by Evonik management as insufficient to begin formal negotiations.

  13. [BUSINESS] 16 sources
    BASF explores potential takeover of Evonik

    BASF has made a non-binding approach to acquire Evonik through a public takeover bid. While contact has been confirmed, no formal negotiations are currently underway, and the RAG-Stiftung's support remains key.

  14. [BUSINESS] 2 sources
    Evonik invests 80 million euros in Slovakian biotechnology plant

    German chemical giant Evonik is investing 80 million euros in its Slovenská Ľupča plant in Slovakia to expand biotechnological capacities for pharmaceutical ingredients.

Sources

4investors.de · ad-hoc-news.de · aktiencheck.de · ariva.de · bilanzmedia.ch · boersennews.de · cash.ch · cashcow.nl · correiodamanhacanada.com · derwesten.de · diario4v.com · dk-online.de · drweb.de · european-coatings.com · fakti.bg · farbeundlack.de · faz.net · fehmarn24.de · finanzen.at · finanzen.ch · finanzen.net · finanzen100.de · finanznachrichten.de · globalriskcommunity.com · hellwegeranzeiger.de · hora1rondonia.com.br · ikz-online.de · interempresas.net · it-boltwise.de · jungewelt.de · kapitalmarktexperten.de · kunststoffweb.de · kurierverlag.de · lokalo.de · m.aktiencheck.de · maschinenmarkt.vogel.de · merca2.es · n-tv.de · newsfeed.zeit.de · nius.de · noz.de · process.vogel.de · pulse2.com · saarbruecker-zeitung.de · sbctv.gr · sharedeals.de · startitup.sk · stocknews.com

This summary has been updated 18 times: see revision history